Status:
RECRUITING
Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease (SCD-TGA)
Lead Sponsor:
BILLOIR
Conditions:
Sickle Cell Disease
Vaso-occlusive Crisis
Eligibility:
All Genders
18+ years
Brief Summary
Sickle cell disease (SCD) is an inherited haemoglobinopathy disorder caused by mutations in HBB gene with amino-acid substitution on β globin chain. The consequence is synthesis of altered haemoglobin...
Eligibility Criteria
Inclusion
- Sickle cell disease
Exclusion
- \<18 years
- pregnancy
- Patient under protective guardianship or curatorship
Key Trial Info
Start Date :
September 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05376046
Start Date
September 1 2018
End Date
September 1 2026
Last Update
May 24 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rouen university Hospital
Rouen, France, 76000